BioLineRx : Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER ...
Stay updated with breaking news from Philip Serlin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER ...
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, May 22, 2024 /PRNewswire/ -- BioLineRx Ltd. , a commercial stage biopharmaceutical company pursuing life-changing therapies in...
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE...
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE...